Lung Cancer Policy Network

HPP acts as secretariat to the Lung Cancer Policy Network, a global multidisciplinary alliance that aims to make lung cancer an international policy priority.

Context

Across the world, lung cancer is responsible for one in five cancer-related deaths – but it is rarely recognised as a priority in health policy.

Lung cancer is among the world’s most common cancers. In 2020 alone, there were 2.2 million new cases of lung cancer globally, and 1.8 million deaths. It is often diagnosed at a late stage, when treatment options are limited.

Early detection of lung cancer, via screening with low-dose computed tomography (LDCT), presents an opportunity to save lives and reduce the significant financial burden of lung cancer on people and societies. Only a few countries have so far committed to implementing lung cancer screening programmes, but many others are considering it.

What we’ve achieved

HPP acts as Secretariat to the Lung Cancer Policy Network, an initiative of the Lung Ambition Alliance set up in 2021. The Network is a global alliance of lung cancer experts, including clinicians, researchers, patient organisations and industry partners.

The Network’s initial goal was to create a community to enable exchange of lessons learnt from the implementation of lung cancer screening. As the Network has developed, our goals have expanded to encompass wider aspects of early detection, care pathways and policy advocacy.

Since 2022, the Network has produced a wide range of resources under three workstreams:

  • Early detection of lung cancer
  • Lung cancer screening
  • Care pathways for lung cancer

As part of the lung cancer screening workstream, the Network has created tools including an interactive map of lung cancer screening, which showcases recent and ongoing clinical trials, implementation studies, and national/regional organised LDCT screening programmes around the world, and a framework to support the implementation of LDCT lung cancer screening, which takes a health systems approach to enable a robust assessment of readiness to implement a lung cancer screening programme.

The interactive map of lung cancer screening was shortlisted as a finalist for the Excellence in Communicating and Using Data category at the 2023 Communiqué Awards.

As Secretariat, HPP created and manages the Lung Cancer Policy Network’s website, X (Twitter), LinkedIn and YouTube accounts.

Key partners and stakeholders

The Lung Cancer Policy Network is a global multidisciplinary alliance. All members donate their time for free. Please visit the Network’s website for a full list of members.

Project funding

The Lung Cancer Policy Network is a global network of multidisciplinary experts from across the lung cancer community, which includes clinicians, researchers, patient organisations and industry partners. The Network is funded by AstraZeneca, Bristol Myers Squibb Foundation, Guardant Health, Intuitive, Johnson & Johnson, MSD and Siemens Healthineers. All Network outputs are non-promotional, evidence based and shaped by the members, who provide their time for free.   

Share